

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jean F.A. Lacrampe et al.  
Serial No. :  
Filed :  
Title : INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES  
  
Art Unit :  
Examiner :

Honorable Commissioner of Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

**In the Specification:**

Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications


This application is a continuation-in-part application of the national stage application filed February 5, 2002, of Application No. PCT/EP00/07358, filed July 31, 2000 which application claims priority from EP 99870170.0, filed August 6, 1999, and EP 99126035.7, filed December 27, 1999. –

**In the Claims:**

Please amend the claims as follows:

3. (Amended) A compound according to claim 1 having the formula

204720 9252001  
10075876 024402



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

*p* represents an integer being 0, 1, 2, 3 or 4;

*X* represents O, S, NR<sup>5</sup> or a direct bond or -X-R<sup>2</sup> taken together may represent cyano;

*Y* represents O, S, NR<sup>5</sup>, or S(O)<sub>2</sub>;

each R<sup>1</sup> independently represents C(=O)-Z-R<sup>14</sup>, C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl, hydroxy, mercapto, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylcarbonyloxy, aryl, cyano, nitro, Het<sup>3</sup>, R<sup>6</sup>, NR<sup>7</sup>R<sup>8</sup> or C<sub>1-4</sub>alkyl substituted with C(=O)-Z-R<sup>14</sup>, Het<sup>3</sup>, R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

R<sup>2</sup> represents Het<sup>1</sup>, C<sub>3-7</sub>cycloalkyl optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with one or two substituents selected from C(=O)-Z-R<sup>14</sup>, hydroxy, cyano, amino, mono- or di(C<sub>1-4</sub>alkyl)amino, C<sub>1-6</sub>alkyloxy optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-6</sub>alkylsulfonyloxy, C<sub>3-7</sub>cycloalkyl optionally substituted with C(=O)-Z-R<sup>14</sup>, aryl, aryloxy, arylthio, Het<sup>1</sup>, Het<sup>1</sup>oxy and Het<sup>1</sup>thio; and if *X* is O, S or NR<sup>5</sup>, then R<sup>2</sup> may also represent aminothiocarbonyl, C<sub>1-4</sub>alkylcarbonyl optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-4</sub>alkylthiocarbonyl optionally substituted with C(=O)-Z-R<sup>14</sup>, arylcarbonyl, arylthiocarbonyl, Het<sup>1</sup>carbonyl or Het<sup>1</sup>thiocarbonyl;

R<sup>3</sup> represents hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl;

R<sup>4</sup> represents hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl; or


R<sup>3</sup> and R<sup>4</sup> taken together form a C<sub>2-6</sub>alkanediyl;

R<sup>5</sup> represents hydrogen or C<sub>1-4</sub>alkyl;


each R<sup>6</sup> independently represents C<sub>1-6</sub>alkylsulfonyl, aminosulfonyl, piperidinylsulfonyl, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfinyl, phenylC<sub>1-4</sub>alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, *N*-C<sub>1-4</sub>alkyl-*N*-piperidinylaminosulfonyl or mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylsulfonyl;

Serial No. 09/\_\_\_\_\_

each  $R^7$  and each  $R^8$  are independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkylcarbonyl, arylcarbonyl, Het<sup>3</sup>carbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het<sup>3</sup>aminocarbonyl, Het<sup>3</sup>aminothiocarbonyl,  $C_{3-7}$ cycloalkyl, pyridinyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkanediyl-C(=O)-Z- $R^{14}$ , -C(=O)-Z- $R^{14}$ , -Y- $C_{1-4}$ alkanediyl-C(=O)-Z- $R^{14}$ , Het<sup>3</sup>, Het<sup>4</sup> and  $R^6$ ; or  $R^7$  and  $R^8$  taken together with the nitrogen atom to which they are attached form a radical of formula



$R^9$  and  $R^{10}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, phenyl, phenyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkylcarbonyl, phenylcarbonyl, Het<sup>3</sup>carbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het<sup>3</sup>aminocarbonyl, Het<sup>3</sup>aminothiocarbonyl,  $C_{3-7}$ cycloalkyl, pyridinyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkanediyl-C(=O)-Z- $R^{14}$ , -C(=O)-Z- $R^{14}$ , -Y- $C_{1-4}$ alkanediyl-C(=O)-Z- $R^{14}$ , Het<sup>3</sup>, Het<sup>4</sup> and  $R^6$ ; or  $R^9$  and  $R^{10}$  taken together with the nitrogen atom to which they are attached form a radical of formula




each  $R^{11}$  independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl,  $C_{1-4}$ alkyloxy optionally substituted with C(=O)-Z- $R^{14}$ , formyl, trihalo $C_{1-4}$ alkylsulfonyloxy,  $R^6$ ,  $NR^7R^8$ , C(=O) $NR^{15}R^{16}$ , -C(=O)-Z- $R^{14}$ , -Y- $C_{1-4}$ alkanediyl-C(=O)-Z- $R^{14}$ , aryl, aryloxy, arylcarbonyl,  $C_{3-7}$ cycloalkyl optionally substituted with


Serial No. 09/\_\_\_\_\_

$C(=O)-Z-R^{14}$ ,  $C_{3-7}$ cycloalkyloxy optionally substituted with  $C(=O)-Z-R^{14}$ , phthalimide-2-yl, Het<sup>3</sup>, Het<sup>4</sup> and  $C(=O)Het^3$ ;


$R^{12}$  and  $R^{13}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, phenyl, phenyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkylcarbonyl, phenylcarbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl,  $C_{3-7}$ cycloalkyl, pyridinyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkanediyl- $C(=O)-Z-R^{14}$ , - $C(=O)-Z-R^{14}$ , -Y- $C_{1-4}$ alkanediyl- $C(=O)-Z-R^{14}$  and  $R^6$ ; or  $R^{12}$  and  $R^{13}$  taken together with the nitrogen atom to which they are attached form a radical of formula




each  $R^{14}$  independently represents hydrogen,  $C_{1-20}$ acyl (having a straight or branched, saturated or unsaturated hydrocarbon chain having 1 to 20 carbon atoms),  $C_{1-20}$ alkyl,  $C_{3-20}$ alkenyl optionally substituted with phenyl,  $C_{3-20}$ alkynyl,  $C_{3-7}$  cycloalkyl, polyhalo $C_{1-20}$ alkyl, Het<sup>5</sup>, phenyl or  $C_{1-20}$  alkyl substituted with one or more substituents selected from hydroxy,  $NR^{17}R^{18}$ , phenyl, mono- or di-( $C_{1-4}$ alkyl)amino, cyano, Het<sup>5</sup>,  $C_{1-4}$  alkyloxycarbonyl, phenyl  $C_{1-4}$  alkyloxycarbonyl and  $C_{3-7}$  cycloalkyl, or  $R^{14}$  represents a radical of formula




(a)




(b)




(c)




(d)




(e)




(h)












(i)



(j)



(k)



wherein m is 1 to 4, n is 0 to 5, q is 0 to 2, r is 0 to 2 and s is 0 to 4;

$R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$  and  $R^f$  are each independently hydrogen,  $C_{1-6}$ alkyl, phenyl or  $C_{3-7}$ cycloalkyl; or

$R^e$  and  $R^f$  taken together may form  $-CH_2-CH_2-$ ,  $-CH_2-CH_2-CH_2-$  or  $-CH_2-CH_2-CH_2-CH_2-$ ;

$R_g$ ,  $R_h$  and  $R_k$  are each independently hydrogen or  $C_{1-4}$  alkyl;

$R_i$  is  $C_{1-4}$ alkyl;


$R_j$  is  $-O-R_b$ ,  $C_{1-6}$ alkyl, phenyl or  $C_{3-7}$ cycloalkyl optionally substituted with  $C_{1-4}$  alkyloxy;

where  $R_m$  is hydrogen or  $C_{1-4}$  alkyloxy and  $R_n$  is hydrogen,  $C_{1-4}$ alkyl,


$C_{3-7}$ cycloalkyl, phenyl or phenyl $C_{1-4}$ alkyl

each Z independently represents O, S, NH,  $-CH_2-O-$  or  $-CH_2-S-$  whereby  $-CH_2-$  is attached to the carbonyl group; or

$-Z-R^{14}$  taken together form a radical of formula




(f)



(g)

$R^{15}$  and  $R^{16}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $-C(=O)-Z-R^{14}$ , arylcarbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, arylaminocarbonyl, arylaminothiocarbonyl, aminocarbonylmethylene, mono- or di( $C_{1-4}$ alkyl) aminocarbonylmethylene, Het<sup>3</sup>amino-carbonyl, Het<sup>3</sup>aminothiocarbonyl, pyridinyl $C_{1-4}$ alkyl, Het<sup>3</sup> or  $R^6$ ; or  $R^{15}$  and  $R^{16}$  taken together with the nitrogen atom to which they are attached form a radical of formula



$R^{17}$  and  $R^{18}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, phenyl, phenyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkylcarbonyl, phenylcarbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl,  $C_{3-7}$ cycloalkyl, pyridinyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkanediyl- $C(=O)-Z-C_{1-6}$ alkyl,  $-C(=O)-Z-C_{1-6}$ alkyl,  $-Y-C_{1-4}$ alkanediyl- $C(=O)-Z-C_{1-6}$ alkyl and  $R^6$ ;

aryl represents phenyl optionally substituted with one, two or three substituents each

independently selected from nitro, azido, cyano, halo, hydroxy,  $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-4}$ alkyloxy, formyl, polyhalo $C_{1-4}$ alkyl,  $NR^9R^{10}$ ,  $C(=O)NR^9R^{10}$ ,  $C(=O)-Z-R^{14}$ ,  $R^6$ ,  $-O-R^6$ , phenyl, Het<sup>3</sup>,  $C(=O)Het^3$  and  $C_{1-4}$ alkyl substituted with one or more substituents each independently selected from halo, hydroxy,  $C_{1-4}$ alkyloxy,  $C(=O)-Z-R^{14}$ ,  $-Y-C_{1-4}$ alkanediyl- $C(=O)-Z-R^{14}$ , Het<sup>3</sup> or  $NR^9R^{10}$ ;

Het<sup>1</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranlyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranlyl, pyridazinyl,

pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with one or two substituents independently selected from Het<sup>2</sup> and R<sup>11</sup>;

Het<sup>2</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>4</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with one or two substituents independently selected from Het<sup>4</sup> and R<sup>11</sup>;

Het<sup>3</sup> represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylcarbonyl, piperidinyl, NR<sup>12</sup>R<sup>13</sup>, C(=O)-Z-R<sup>14</sup>, R<sup>6</sup> and C<sub>1-4</sub>alkyl substituted with one or two substituents independently selected from hydroxy, C<sub>1-4</sub>alkyloxy, phenyl, C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, R<sup>6</sup> and NR<sup>12</sup>R<sup>13</sup>;

Het<sup>4</sup> represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl;



Het<sup>5</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylcarbonyl, piperidinyl, NR<sup>17</sup>R<sup>18</sup>, C(=O)-Z-C<sub>1-6</sub>alkyl, R<sup>6</sup>, sulfonamido and C<sub>1-4</sub>alkyl substituted with one or two substituents independently selected from hydroxy, C<sub>1-4</sub>alkyloxy, phenyl, C(=O)-Z-C<sub>1-6</sub>alkyl, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-C<sub>1-6</sub>alkyl, R<sup>6</sup> and NR<sup>17</sup>R<sup>18</sup> ; provided however that

- R<sup>2</sup> is other than C<sub>1-6</sub> alkyloxycarbonylC<sub>1-6</sub>alkyl or aminocarbonyl; and
- R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are other than aminocarbonyl, C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkyloxycarbonylcarbonyl, C(=O)-O-R<sup>19</sup>, C<sub>1-4</sub>alkanediylC(=O)-O-R<sup>19</sup> or -Y-C<sub>1-4</sub>alkanediylC(=O)-O-R<sup>19</sup>; and
- R<sup>12</sup> and R<sup>13</sup> are other than C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl or C<sub>1-4</sub>alkylcarbonylcarbonyl; and
- R<sup>11</sup> is other than C(=O)-O-R<sup>19</sup>, Y-C<sub>1-4</sub>alkanediyl - C(=O)-OR<sup>19</sup>, C(=O)NH<sub>2</sub>, C(=O)NHC<sub>1-4</sub>alkyl or C(=O)NHC<sub>3-7</sub>cycloalkyl; and
- R<sup>15</sup> and R<sup>16</sup> are other than aminocarbonyl, C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl or C<sub>1-4</sub>alkyloxycarbonylcarbonyl; and
- aryl is other than phenyl substituted with C(=O)-O-R<sup>19</sup>, C(=O)NH<sub>2</sub>, C(=O)NHC<sub>1-4</sub>alkyl, C(=O)NHC<sub>3-7</sub>cycloalkyl and/or with C<sub>1-4</sub>alkyl substituted with C(=O)-O-R<sup>19</sup> or Y-C<sub>1-4</sub>alkanediyl - C(=O)-O-R<sup>14</sup>; and
- Het<sup>3</sup> is other than a monocyclic heterocycle substituted with C(=O)-O-R<sup>19</sup> and/or with C<sub>1-4</sub>alkyl substituted with C(=O)-O-R<sup>19</sup> and/or Y-C<sub>1-4</sub>alkanediyl - (=O)-O-R<sup>19</sup>; and

Serial No. 09/\_\_\_\_\_

- in each of the above proviso's R<sup>19</sup> is defined as hydrogen, C<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, aminocarbonylmethylene or mono- or di(C<sub>1-4</sub>alkyl)aminocarbonylmethylene; and
  - the said compound of formula (I) contains at least one – C(=O)-Z-R<sup>14</sup> moiety.
4. (Amended) A compound according to claim 1 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
5. (Amended) A compound according to claim 1 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.
6. (Amended) A compound according to claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.
7. (Amended) A compound according to claim 1 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.
8. (Amended) A compound according to claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
11. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

Please cancel claims 12 and 13.

Serial No. 09/\_\_\_\_\_

14. (Amended) A method for treating eosinophil-dependent inflammatory diseases comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
17. (Amended) A process of imaging an organ, comprising, administering a sufficient amount of a radiolabelled compound of formula (I) as claimed in claim 1 in an appropriate composition, and detecting the emissions from the radioactive compound.

Please cancel claims 19 and 20.

Serial No. 09/ \_\_\_\_\_

**REMARKS/ARGUMENTS**

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

By this Amendment, claims 12, 13, 19 and 20 were canceled. Accordingly, the pending claims are 1-11, and 14-18.

The specification has been amended to refer to the priority applications.

Enclosed herewith is an Information Disclosure Statement with a copy of the International Search Report and documents cited therein.


Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: \_\_\_\_\_



Ellen Ciambrone Coletti

Reg. No. 34,140

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2359  
Dated: February 14, 2002

201720-92852001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**


Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications

This application is a continuation-in-part application of the national stage application filed February 5, 2002, of Application No. PCT/EP00/07358, filed July 31, 2000 which application claims priority from EP 99870170.0, filed August 6, 1999, and EP 99126035.7, filed December 27, 1999. –

**In the Claims:**

3. (Amended) A compound according to claim[s] 1 [or 2] having the formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

*p* represents an integer being 0, 1, 2, 3 or 4;

*X* represents O, S, NR<sup>5</sup> or a direct bond or -X-R<sup>2</sup> taken together may represent cyano;

*Y* represents O, S, NR<sup>5</sup>, or S(O)<sub>2</sub>;

each R<sup>1</sup> independently represents C(=O)·Z-R<sup>14</sup>, C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl, hydroxy, mercapto, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylcarbonyloxy, aryl, cyano, nitro, Het<sup>3</sup>, R<sup>6</sup>, NR<sup>7</sup>R<sup>8</sup> or C<sub>1-4</sub>alkyl substituted with C(=O)-Z·R<sup>14</sup>, Het<sup>3</sup>, R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

R<sup>2</sup> represents Het<sup>1</sup>, C<sub>3-7</sub>cycloalkyl optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with one or two substituents selected from C(=O)·Z-R<sup>14</sup>, hydroxy,

cyano, amino, mono- or di(C<sub>1-4</sub>alkyl)amino, C<sub>1-6</sub>alkyloxy optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-6</sub>alkylsulfonyloxy, C<sub>3-7</sub>cycloalkyl optionally substituted with C(=O)-Z-R<sup>14</sup>, aryl, aryloxy, arylthio, Het<sup>1</sup>, Het<sup>1</sup>oxy and Het<sup>1</sup>thio; and if X is O, S or NR<sup>5</sup>, then R<sup>2</sup> may also represent aminothiocarbonyl, C<sub>1-4</sub>alkylcarbonyl optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>1-4</sub>alkylthiocarbonyl optionally substituted with C(=O)-Z-R<sup>14</sup>, arylcarbonyl, arylthiocarbonyl, Het<sup>1</sup>carbonyl or Het<sup>1</sup>thiocarbonyl;

R<sup>3</sup> represents hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl;


R<sup>4</sup> represents hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl; or

R<sup>3</sup> and R<sup>4</sup> taken together form a C<sub>2-6</sub>alkanediyl;

R<sup>5</sup> represents hydrogen or C<sub>1-4</sub>alkyl;

each R<sup>6</sup> independently represents C<sub>1-6</sub>alkylsulfonyl, aminosulfonyl, piperidinylsulfonyl, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfinyl, phenylC<sub>1-4</sub>alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, N-C<sub>1-4</sub>alkyl-N-piperidinylaminosulfonyl or mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylsulfonyl;


each R<sup>7</sup> and each R<sup>8</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, dihydroxyC<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyl, arylcarbonyl, Het<sup>3</sup>carbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het<sup>3</sup>aminocarbonyl, Het<sup>3</sup>aminothiocarbonyl, C<sub>3-7</sub>cycloalkyl, pyridinylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, -C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, Het<sup>3</sup>, Het<sup>4</sup> and R<sup>6</sup>; or R<sup>7</sup> and R<sup>8</sup> taken together with the nitrogen atom to which they are attached form a radical of formula



R<sup>9</sup> and R<sup>10</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, dihydroxyC<sub>1-4</sub>alkyl, phenyl, phenylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyl,


Serial No. 09/\_\_\_\_\_

phenylcarbonyl, Het<sup>3</sup>carbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het<sup>3</sup>aminocarbonyl, Het<sup>3</sup>aminothiocarbonyl, C<sub>3-7</sub>cycloalkyl, pyridinylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, -C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, Het<sup>3</sup>, Het<sup>4</sup> and R<sup>6</sup>; or R<sup>9</sup> and R<sup>10</sup> taken together with the nitrogen atom to which they are attached form a radical of formula




each R<sup>11</sup> independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C<sub>1-4</sub>alkyloxy optionally substituted with C(=O)-Z-R<sup>14</sup>, formyl, trihaloC<sub>1-4</sub>alkylsulfonyloxy, R<sup>6</sup>, NR<sup>7</sup>R<sup>8</sup>, C(=O)NR<sup>15</sup>R<sup>16</sup>, -C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, aryl, aryloxy, arylcarbonyl, C<sub>3-7</sub>cycloalkyl optionally substituted with C(=O)-Z-R<sup>14</sup>, C<sub>3-7</sub>cycloalkyloxy optionally substituted with C(=O)-Z-R<sup>14</sup>, phthalimide-2-yl, Het<sup>3</sup>, Het<sup>4</sup> and C(=O)Het<sup>3</sup>;

R<sup>12</sup> and R<sup>13</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, dihydroxyC<sub>1-4</sub>alkyl, phenyl, phenylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyl, phenylcarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C<sub>3-7</sub>cycloalkyl, pyridinylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, -C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup> and R<sup>6</sup>; or R<sup>12</sup> and R<sup>13</sup> taken together with the nitrogen atom to which they are attached form a radical of formula




each R<sup>14</sup> independently represents hydrogen, C<sub>1-20</sub>acyl (having a straight or branched, saturated or unsaturated hydrocarbon chain having 1 to 20 carbon atoms), C<sub>1-20</sub>alkyl,


C<sub>3-20</sub>alkenyl optionally substituted with phenyl, C<sub>3-20</sub>alkynyl, C<sub>3-7</sub> cycloalkyl, polyhaloC<sub>1-20</sub>alkyl, Het<sup>5</sup>, phenyl or C<sub>1-20</sub> alkyl substituted with one or more substituents selected from hydroxy, NR<sup>17</sup>R<sup>18</sup>, phenyl, mono- or di-(C<sub>1-4</sub>alkyl)amino, cyano, Het<sup>5</sup>, C<sub>1-4</sub>alkyloxycarbonyl, phenyl C<sub>1-4</sub>alkyloxycarbonyl and C<sub>3-7</sub> cycloalkyl, or R<sup>14</sup> represents a radical of formula




(a)




(b)




(c)




(d)




(e)




(h)



(i)












(j)



(k)





wherein m is 1 to 4, n is 0 to 5, q is 0 to 2, r is 0 to 2 and s is 0 to 4;

$R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$  and  $R^f$  are each independently hydrogen,  $C_{1-6}$ alkyl, phenyl or  $C_{3-7}$ cycloalkyl; or

$R^e$  and  $R^f$  taken together may form  $-CH_2-CH_2-$ ,  $-CH_2-CH_2-CH_2-$  or  $-CH_2-CH_2-CH_2-CH_2-$ ;

$R_g$ ,  $R_h$  and  $R_k$  are each independently hydrogen or  $C_{1-4}$  alkyl;

$R_i$  is  $C_{1-4}$ alkyl;


$R_j$  is  $-O-R_b$ ,  $C_{1-6}$ alkyl, phenyl or  $C_{3-7}$ cycloalkyl optionally substituted with  $C_{1-4}$  alkyloxy;

where  $R_m$  is hydrogen or  $C_{1-4}$  alkyloxy and  $R_n$  is hydrogen,  $C_{1-4}$ alkyl,


$C_{3-7}$ cycloalkyl, phenyl or phenyl $C_{1-4}$ alkyl

each Z independently represents O, S, NH,  $-CH_2-O-$  or  $-CH_2-S-$  whereby  $-CH_2-$  is attached to the carbonyl group; or

$-Z-R^{14}$  taken together form a radical of formula



$R^{15}$  and  $R^{16}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $-C(=O)-Z-R^{14}$ , arylcarbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, arylaminocarbonyl, arylaminothiocarbonyl, aminocarbonylmethylene, mono- or di( $C_{1-4}$ alkyl) aminocarbonylmethylene, Het<sup>3</sup>amino-carbonyl, Het<sup>3</sup>aminothiocarbonyl, pyridinyl $C_{1-4}$ alkyl, Het<sup>3</sup> or  $R^6$ ; or  $R^{15}$  and  $R^{16}$  taken together with the nitrogen atom to which they are attached form a radical of formula



$R^{17}$  and  $R^{18}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkyl, dihydroxy $C_{1-4}$ alkyl, phenyl, phenyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkylcarbonyl, phenylcarbonyl, mono- or di( $C_{1-4}$ alkyl)amino $C_{1-4}$ alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl,  $C_{3-7}$ cycloalkyl, pyridinyl $C_{1-4}$ alkyl,  $C_{1-4}$ alkanediyl- $C(=O)-Z-C_{1-6}$ alkyl,  $-C(=O)-Z-C_{1-6}$ alkyl,  $-Y-C_{1-4}$ alkanediyl- $C(=O)-Z-C_{1-6}$ alkyl and  $R^6$ ;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, cyano, halo, hydroxy,  $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-4}$ alkyloxy, formyl, polyhalo $C_{1-4}$ alkyl,  $NR^9R^{10}$ ,  $C(=O)NR^9R^{10}$ ,  $C(=O)-Z-R^{14}$ ,  $R^6$ ,  $-O-R^6$ , phenyl, Het<sup>3</sup>,  $C(=O)Het^3$  and  $C_{1-4}$ alkyl substituted with one or more substituents each independently selected from halo, hydroxy,  $C_{1-4}$ alkyloxy,  $C(=O)-Z-R^{14}$ ,  $-Y-C_{1-4}$ alkanediyl- $C(=O)-Z-R^{14}$ , Het<sup>3</sup> or  $NR^9R^{10}$ ;

Het<sup>1</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazoliny, pyrazolyl, pyrazoliny, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazoliny, isoxazolyl, thiazolyl, thiazoliny, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl,

pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with one or two substituents independently selected from Het<sup>2</sup> and R<sup>11</sup>;

Het<sup>2</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>4</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with one or two substituents independently selected from Het<sup>4</sup> and R<sup>11</sup>;

Het<sup>3</sup> represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylcarbonyl, piperidinyl, NR<sup>12</sup>R<sup>13</sup>, C(=O)-Z-R<sup>14</sup>, R<sup>6</sup> and C<sub>1-4</sub>alkyl substituted with one or two substituents independently selected from hydroxy, C<sub>1-4</sub>alkyloxy, phenyl, C(=O)-Z-R<sup>14</sup>, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-R<sup>14</sup>, R<sup>6</sup> and NR<sup>12</sup>R<sup>13</sup>;

Het<sup>4</sup> represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl;

Het<sup>5</sup> represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-*b*]thiazolyl; wherein said heterocycles each independently may be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylcarbonyl, piperidinyl, NR<sup>17</sup>R<sup>18</sup>, C(=O)-Z-C<sub>1-6</sub>alkyl, R<sup>6</sup>, sulfonamido and C<sub>1-4</sub>alkyl substituted with one or two substituents independently selected from hydroxy, C<sub>1-4</sub>alkyloxy, phenyl, C(=O)-Z-C<sub>1-6</sub>alkyl, -Y-C<sub>1-4</sub>alkanediyl-C(=O)-Z-C<sub>1-6</sub>alkyl, R<sup>6</sup> and NR<sup>17</sup>R<sup>18</sup> ; provided however that

- R<sup>2</sup> is other than C<sub>1-6</sub> alkyloxycarbonylC<sub>1-6</sub>alkyl or aminocarbonyl; and
- R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are other than aminocarbonyl, C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkyloxycarbonylcarbonyl, C(=O)-O-R<sup>19</sup>, C<sub>1-4</sub>alkanediylC(=O)-O-R<sup>19</sup> or -Y-C<sub>1-4</sub>alkanediylC(=O)-O-R<sup>19</sup>; and
- R<sup>12</sup> and R<sup>13</sup> are other than C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl or C<sub>1-4</sub>alkylcarbonylcarbonyl; and
- R<sup>11</sup> is other than C(=O)-O-R<sup>19</sup>, Y-C<sub>1-4</sub>alkanediyl - C(=O)-OR<sup>19</sup>, C(=O)NH<sub>2</sub>, C(=O)NHC<sub>1-4</sub>alkyl or C(=O)NHC<sub>3-7</sub>cycloalkyl; and
- R<sup>15</sup> and R<sup>16</sup> are other than aminocarbonyl, C<sub>1-4</sub>alkylcarbonyloxy-C<sub>1-4</sub>alkylcarbonyl, hydroxy C<sub>1-4</sub>alkylcarbonyl or C<sub>1-4</sub>alkyloxycarbonylcarbonyl; and
- aryl is other than phenyl substituted with C(=O)-O-R<sup>19</sup>, C(=O)NH<sub>2</sub>, C(=O)NHC<sub>1-4</sub>alkyl, C(=O)NHC<sub>3-7</sub>cycloalkyl and/or with C<sub>1-4</sub>alkyl substituted with C(=O)-O-R<sup>19</sup> or Y-C<sub>1-4</sub>alkanediyl - C(=O)-O-R<sup>14</sup>; and
- Het<sup>3</sup> is other than a monocyclic heterocycle substituted with C(=O)-O-R<sup>19</sup> and/or with C<sub>1-4</sub>alkyl substituted with C(=O)-O-R<sup>19</sup> and/or Y-C<sub>1-4</sub>alkanediyl - (=O)-O-R<sup>19</sup>; and

Serial No. 09/\_\_\_\_\_

- in each of the above proviso's R<sup>19</sup> is defined as hydrogen, C<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, aminocarbonylmethylene or mono- or di(C<sub>1-4</sub>alkyl)aminocarbonylmethylene; and
  - the said compound of formula (I) contains at least one – C(=O)-Z-R<sup>14</sup> moiety.
4. (Amended) A compound according to [any of] claim[s] 1 [to 3] wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
5. (Amended) A compound according to [any of] claim[s] 1 [to 4] wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.
6. (Amended) A compound according to [any of] claim[s] 1 [to 5] wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.
7. (Amended) A compound according to [any of] claim[s] 1 [to 6] wherein p is 1 or 2 and each R<sup>1</sup> is chloro.
8. (Amended) A compound according to [any of] claim[s] 1 [to 7] wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
11. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to [any of] claim[s] 1 [to 10].

Serial No. 09/\_\_\_\_\_

Please cancel claims 12 and 13.

14. (Amended) [Use of a compound according to any of claims 1 to 10 in the manufacture of a medicament] A method for treating eosinophil-dependent inflammatory diseases comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
17. (Amended) A process of imaging an organ, [characterized by] comprising, administering a sufficient amount of a radiolabelled compound of formula (I) as claimed in claim 1 in an appropriate composition, and detecting the emissions from the radioactive compound.

Please cancel claims 19 and 20.